Madison, WI – Voximetry, a Healthtech innovator advancing personalized dosimetry for radiopharmaceutical therapy (RPT), today announced the expansion and evolution of its Board of Directors in alignment with its global growth strategy. With this move, the Company has grown its Board from four to five members, welcoming three accomplished leaders with deep experience in radiopharmaceutical science, entrepreneurship, and capital strategy.
As part of this transition:
- Dr. Sue Wallace, who successfully led the company as CEO, has been appointed Executive Chair of the Board.
- Paul Wickre, co-founder and Chief Technology Officer of Voximetry, continues as Director.
- Andreas Schulte, recently appointed Chief Executive Officer, has joined the Board of Directors.
- Two co-founders have stepped down from the Board. They are succeeded by Dr. Frances Johnson and Rick Wolfen.
Frances Johnson, MD has held executive leadership roles at Perspective Therapeutics and Viewpoint Molecular Targeting. A physician-scientist and entrepreneur, she has founded two healthcare technology companies and successfully scaled them through equity financing and public exits, in addition to leading academic programs.
Rick Wolfen is an experienced investor and strategic leader. He is the Managing Member of Sea Glass Ventures, an early-stage venture capital fund, and serves as Founder and President of Rock Asset Management, a commercial real estate investment and management company. He currently holds several board positions and is active in philanthropy through the Wolfen Family Foundation.
Andreas Schulte brings more than 30 years of experience developing new software application markets worldwide, with a focus on Radiation Oncology and Theranostics dosimetry. He has a proven track record of driving growth through clear market entry strategies and a strong international network. He holds a Master’s degree in Theoretical Nuclear Physics.
“Rebuilding and expanding our Board ensures we have the right balance of scientific insight, operational leadership, and capital strategy to guide Voximetry through its next phase of growth,” said Wallace. “We are grateful to our founding directors for their invaluable contributions in establishing Voximetry as the leading authority on advanced dosimetry, and we are confident about the future as we welcome leaders with deep experience in corporate growth to the table.”
The enhanced Board of Directors will support Voximetry as it advances its mission to make routine dosimetry a reality for every RPT provider and patient worldwide.
About Voximetry
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering advanced dosimetry to enable patient-specific radiopharmaceutical therapy (RPT) in cancer patients.
For media inquiries, please contact marketing@voximetry.com.